FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079403881> ?p ?o ?g. }

• W2079403881 endingPage "911" @default.
• W2079403881 startingPage "910" @default.
• W2079403881 abstract "Cervical cancer is the second most common cancer in women worldwide, with about 500 000 new cases each year. Mortality is higher in developing countries than in developed countries, with around 200 000 deaths reported a year compared with 70 000 in developed countries. Half of the cases of cervical cancer that are identified every year occur in women who have not been properly screened either because of low coverage of Papanicolaou testing, the limitations of such testing (including insufficient quality control of the procedure), or limited access to health facilities for screening and treatment. Therefore, to search for alternative technologies to screen for cervical cancer is essential. Establishment of the causal link between high-risk human papillomaviruses (HPV) and cervical cancer 1 Bosch FX de Sanjosé S Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; 31: 3-13 Crossref PubMed Scopus (723) Google Scholar sets the basis for new areas of research that include the application of HPV testing and biomarkers to identify women at high risk of progression to cervical cancer and its precursors. Testing for high-risk HPV is more sensitive and has a higher negative predictive value to detect the immediate precursors of cervical cancer (high-grade cervical intraepithelial neoplasia; CIN2/3) than cervical cytology, at the cost of a small decrease in specificity and positive predictive value. 2 Cuzick J Mayrand MH Ronco G Snijders P Wardle J Chapter 10: New dimensions in cervical cancer screening. Vaccine. 2006; 24: 90-97 Crossref PubMed Scopus (120) Google Scholar Several studies have shown that HPV testing is more efficient than repeated cytology in the triage of ambiguous cytological lesions, is at least as efficient as cytology when used a primary screening test, and is more efficient than cytology as a test of follow-up for recurrence after treatment for pre-invasive lesions of the cervix. 3 Cuzick J Clavel C Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101 Crossref PubMed Scopus (854) Google Scholar , 4 Mayrand MH Duarte-Franco E Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588 Crossref PubMed Scopus (820) Google Scholar , 5 Bulkmans NW Berkhof J Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370: 1764-1772 Summary Full Text Full Text PDF PubMed Scopus (531) Google Scholar A critical review and recommendations for the clinical utility of HPV testing, as well as other cervical-cancer screening tools, is available. 6 International Agency for Research on Cancer (IARC)IARC handbook of cancer prevention. Volume 10. Cervical cancer screening. IARC Press, Lyon, France2005 Google Scholar However, its use in primary screening or triage of women with cervical abnormalities has been hampered by the cost of the available tests, the logistics involved, and the time taken to do the test, particularly in low-resource settings. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural ChinaThe careHPV test is promising as a primary screening method for cervical-cancer prevention in low-resource regions. Full-Text PDF Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trialHPV testing with p16-INK4A triage produces a significant increase in sensitivity compared with conventional cytology, with no substantial increase in referral to colposcopy. Full-Text PDF" @default.
• W2079403881 created "2016-06-24" @default.
• W2079403881 creator A5078214986 @default.
• W2079403881 date "2008-10-01" @default.
• W2079403881 modified "2023-09-27" @default.
• W2079403881 title "Assessment of new technologies for cervical cancer screening" @default.
• W2079403881 cites W1966498345 @default.
• W2079403881 cites W1967933229 @default.
• W2079403881 cites W1974570262 @default.
• W2079403881 cites W1990879009 @default.
• W2079403881 cites W2008890733 @default.
• W2079403881 cites W2016485902 @default.
• W2079403881 cites W2038550499 @default.
• W2079403881 cites W2038986660 @default.
• W2079403881 cites W2045950883 @default.
• W2079403881 cites W2095250514 @default.
• W2079403881 cites W2099888955 @default.
• W2079403881 cites W2111855638 @default.
• W2079403881 cites W2114212562 @default.
• W2079403881 cites W2166467087 @default.
• W2079403881 cites W2481961322 @default.
• W2079403881 doi "https://doi.org/10.1016/s1470-2045(08)70238-9" @default.
• W2079403881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19071241" @default.
• W2079403881 hasPublicationYear "2008" @default.
• W2079403881 type Work @default.
• W2079403881 sameAs 2079403881 @default.
• W2079403881 citedByCount "8" @default.
• W2079403881 countsByYear W20794038812012 @default.
• W2079403881 countsByYear W20794038812013 @default.
• W2079403881 countsByYear W20794038812014 @default.
• W2079403881 crossrefType "journal-article" @default.
• W2079403881 hasAuthorship W2079403881A5078214986 @default.
• W2079403881 hasConcept C121608353 @default.
• W2079403881 hasConcept C126322002 @default.
• W2079403881 hasConcept C131872663 @default.
• W2079403881 hasConcept C143998085 @default.
• W2079403881 hasConcept C2777343196 @default.
• W2079403881 hasConcept C2778220009 @default.
• W2079403881 hasConcept C2780647465 @default.
• W2079403881 hasConcept C29456083 @default.
• W2079403881 hasConcept C2993522905 @default.
• W2079403881 hasConcept C65051434 @default.
• W2079403881 hasConcept C71924100 @default.
• W2079403881 hasConceptScore W2079403881C121608353 @default.
• W2079403881 hasConceptScore W2079403881C126322002 @default.
• W2079403881 hasConceptScore W2079403881C131872663 @default.
• W2079403881 hasConceptScore W2079403881C143998085 @default.
• W2079403881 hasConceptScore W2079403881C2777343196 @default.
• W2079403881 hasConceptScore W2079403881C2778220009 @default.
• W2079403881 hasConceptScore W2079403881C2780647465 @default.
• W2079403881 hasConceptScore W2079403881C29456083 @default.
• W2079403881 hasConceptScore W2079403881C2993522905 @default.
• W2079403881 hasConceptScore W2079403881C65051434 @default.
• W2079403881 hasConceptScore W2079403881C71924100 @default.
• W2079403881 hasIssue "10" @default.
• W2079403881 hasLocation W20794038811 @default.
• W2079403881 hasLocation W20794038812 @default.
• W2079403881 hasOpenAccess W2079403881 @default.
• W2079403881 hasPrimaryLocation W20794038811 @default.
• W2079403881 hasRelatedWork W1982636135 @default.
• W2079403881 hasRelatedWork W2018555639 @default.
• W2079403881 hasRelatedWork W2040425118 @default.
• W2079403881 hasRelatedWork W2105497721 @default.
• W2079403881 hasRelatedWork W2119147736 @default.
• W2079403881 hasRelatedWork W2121600189 @default.
• W2079403881 hasRelatedWork W2343557271 @default.
• W2079403881 hasRelatedWork W2759875907 @default.
• W2079403881 hasRelatedWork W2945163408 @default.
• W2079403881 hasRelatedWork W2974574331 @default.
• W2079403881 hasVolume "9" @default.
• W2079403881 isParatext "false" @default.
• W2079403881 isRetracted "false" @default.
• W2079403881 magId "2079403881" @default.
• W2079403881 workType "article" @default.